Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Fig. 4

CSF endo-lysosomal proteins and ubiquitin concentrations in clinical study II. Clinical study II included cross-sectional samples from clinically characterized subjects with AD (N = 36) and PD (N = 11) as well as cognitively normal healthy controls (N = 44). A significant decreased concentration of a AP2B1_712–719 (P < 0.001), b AP2B1_835–842 (P < 0.001), c C9_232–242 (P < 0.05), d CTSB_80–87 (P < 0.05), e CTSF_103–116 (P = 0.001), f CTSF_236–245 (P < 0.01), g CTSF_266–278 (P < 0.01), h CTSF_442–450 (P < 0.01), i GM2A_89–96 (P < 0.0001), j GM2A_170–179 (P < 0.0001), k TCN2_45–59 (P < 0.05), l TCN2_300–313 (P < 0.05), m Ubiquitin_12–27 (P < 0.001), and n Ubiquitin_64–72 (P < 0.001) was found in PD compared to AD. Additionally, a significant decreased concentration of a AP2B1_712–719 (P < 0.01), b AP2B1_835–842 (P < 0.05), e CTSF_103–116 (P < 0.05), h CTSF_442–450 (P < 0.05), i GM2A_89–96 (P < 0.0001), j GM2A_170–179 (P < 0.001), and n Ubiquitin_64–72 (P < 0.05) was identified in PD compared to controls. Statistics were calculated using Kruskal-Wallis test with Dunn’s test for multiple comparisons and the graphs show Tukey boxplots

Back to article page